Stockscreener 앱 받기
175.26
0.37%
0.65
전일 마감가:
$174.61
열려 있는:
$177.22
하루 거래량:
118.30K
Relative Volume:
0.50
시가총액:
$6.57B
수익:
-
순이익/손실:
$-32.61M
주가수익비율:
-149.26
EPS:
-1.1742
순현금흐름:
-
1주 성능:
-6.71%
1개월 성능:
+11.67%
6개월 성능:
+144.91%
1년 성능:
+209.81%
1일 변동 폭
$171.35
$177.22
1주일 범위
$168.00
$189.99
52주 변동 폭
$49.00
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
175.26 | 6.55B | 0 | -32.61M | 0 | -1.1742 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-26 | 개시 | BofA Securities | Buy |
| 2026-01-06 | 개시 | Morgan Stanley | Overweight |
| 2025-12-02 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-11-20 | 개시 | Mizuho | Neutral |
| 2023-12-14 | 개시 | Maxim Group | Buy |
| 2023-07-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 개시 | SVB Securities | Outperform |
| 2022-08-01 | 개시 | H.C. Wainwright | Buy |
| 2022-07-01 | 개시 | The Benchmark Company | Buy |
모두보기
Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Short Interest Up 49.4% in January - MarketBeat
Why (BLTE) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Belite Bio (NASDAQ:BLTE) Shares Down 5.2%Here's Why - MarketBeat
Belite Bio (BLTE) Valuation Check After Completing Enrollment In Pivotal DRAGON II Trial - Sahm
Belite Bio stock hits all-time high at 177.28 USD By Investing.com - Investing.com Nigeria
Belite Bio stock hits all-time high at 177.28 USD - Investing.com
Belite Bio (NASDAQ:BLTE) Reaches New 12-Month HighHere's What Happened - MarketBeat
Belite Bio (BLTE) Valuation Check As Phase 3 DRAGON Tinlarebant Data Presentations Approach - Sahm
Understanding Momentum Shifts in (BLTE) - Stock Traders Daily
Belite Bio Announces Participation at the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO) - markets.businessinsider.com
H.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target By Investing.com - Investing.com South Africa
H.C. Wainwright reiterates Buy rating on Belite Bio stock with $185 target - Investing.com Nigeria
Belite Bio's (BLTE) Buy Rating Reiterated at HC Wainwright - MarketBeat
Belite Bio completes enrollment in phase 2/3 STGD1 drug trial - Investing.com India
Belite Bio Completes Global Enrollment in DRAGON II Tinlarebant Trial for Stargardt Disease - TipRanks
Belite Bio (NASDAQ:BLTE) Now Covered by Bank of America - Defense World
Belite Bio (NASDAQ:BLTE) Reaches New 1-Year HighStill a Buy? - MarketBeat
Belite Bio Surges on Breakthrough Eye Drug Hopes - TipRanks
Belite Bio stock hits all-time high at $170.35 - Investing.com
Belite Bio stock hits all-time high at $170.35 By Investing.com - Investing.com UK
BofA Securities initiates coverage on Belite Bio stock with Buy rating - Investing.com Canada
BofA Securities initiates coverage on Belite Bio stock with Buy rating By Investing.com - Investing.com South Africa
Avoiding Lag: Real-Time Signals in (BLTE) Movement - Stock Traders Daily
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
High Net Worth Advisory Group LLC Invests $259,000 in Belite Bio, Inc. Sponsored ADR $BLTE - Defense World
Assessing Belite Bio (BLTE) Valuation As Tinlarebant Progress And Pricing Plans Take Shape - Sahm
Dry Age Macular Degeneration Pipeline 2025: Key Companies, MOA, - openPR.com
Cantor Fitzgerald reiterates Overweight rating on Belite Bio stock By Investing.com - Investing.com Nigeria
Cantor Fitzgerald reiterates Overweight rating on Belite Bio stock - Investing.com
Belite Bio, Inc (BLTE) Stock Analysis: A Biotech Gem With 19.70% Upside Potential - DirectorsTalk Interviews
Discipline and Rules-Based Execution in BLTE Response - Stock Traders Daily
Belite Bio Reports Breakthrough Phase 3 Results for Stargardt Disease Treatment - MSN
Belite Bio stock hits all-time high at 169.88 USD By Investing.com - Investing.com Nigeria
Belite Bio stock hits all-time high at 169.88 USD - Investing.com
Morgan Stanley initiates Belite Bio stock with Overweight rating, $191 target - Investing.com Nigeria
Belite Bio (NASDAQ:BLTE) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Morgan Stanley initiates Belite Bio stock with Overweight rating, $191 target By Investing.com - Investing.com Canada
Belite Bio (NASDAQ:BLTE) Sets New 12-Month HighTime to Buy? - MarketBeat
Behavioral Patterns of BLTE and Institutional Flows - Stock Traders Daily
Belite Bio (NASDAQ:BLTE) Shares Up 5.5%Should You Buy? - MarketBeat
Belite Bio stock hits all-time high at 163.25 USD - Investing.com
Belite Bio stock hits all-time high at 163.25 USD By Investing.com - Investing.com Australia
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Short Interest Down 45.2% in December - MarketBeat
Belite Bio Inc Adr (BLTE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):